1. Home
  2. AUPH vs GB Comparison

AUPH vs GB Comparison

Compare AUPH & GB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AUPH
  • GB
  • Stock Information
  • Founded
  • AUPH 1993
  • GB 1980
  • Country
  • AUPH Canada
  • GB Switzerland
  • Employees
  • AUPH N/A
  • GB N/A
  • Industry
  • AUPH Biotechnology: Pharmaceutical Preparations
  • GB EDP Services
  • Sector
  • AUPH Health Care
  • GB Technology
  • Exchange
  • AUPH Nasdaq
  • GB Nasdaq
  • Market Cap
  • AUPH 1.1B
  • GB 1.5B
  • IPO Year
  • AUPH 1999
  • GB N/A
  • Fundamental
  • Price
  • AUPH $7.49
  • GB $7.48
  • Analyst Decision
  • AUPH Strong Buy
  • GB Buy
  • Analyst Count
  • AUPH 2
  • GB 1
  • Target Price
  • AUPH $11.50
  • GB $6.00
  • AVG Volume (30 Days)
  • AUPH 1.5M
  • GB 128.8K
  • Earning Date
  • AUPH 07-31-2025
  • GB 06-04-2025
  • Dividend Yield
  • AUPH N/A
  • GB N/A
  • EPS Growth
  • AUPH N/A
  • GB 483.33
  • EPS
  • AUPH 0.27
  • GB 0.38
  • Revenue
  • AUPH $247,295,000.00
  • GB $548,939,689.00
  • Revenue This Year
  • AUPH $12.15
  • GB $15.17
  • Revenue Next Year
  • AUPH $18.31
  • GB $6.50
  • P/E Ratio
  • AUPH $28.12
  • GB $19.77
  • Revenue Growth
  • AUPH 29.20
  • GB 20.26
  • 52 Week Low
  • AUPH $5.20
  • GB $4.29
  • 52 Week High
  • AUPH $10.67
  • GB $8.00
  • Technical
  • Relative Strength Index (RSI)
  • AUPH 37.76
  • GB 56.50
  • Support Level
  • AUPH $7.71
  • GB $7.46
  • Resistance Level
  • AUPH $8.86
  • GB $7.49
  • Average True Range (ATR)
  • AUPH 0.34
  • GB 0.02
  • MACD
  • AUPH -0.04
  • GB 0.00
  • Stochastic Oscillator
  • AUPH 13.02
  • GB 66.67

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About GB Global Blue Group Holding AG

Global Blue Group Holding AG offers a seamless shopping and payment journey for tourists and also provides a wide range of Added-Value Payment Solutions for all the stakeholders involved, including retailers and international shoppers. The company connect thousands of retailers, acquirers, and hotels with nearly 80 million consumers across more than 50 countries, in three industries: Tax Free Shopping, Payments and Post-Purchase solutions.

Share on Social Networks: